Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2068015

COc1ccc2[nH]c([C@H]3C[C@H](NC(=O)Nc4ccc(C)nc4)CCN3C3CCC3)nc2c1.O=C(O)C(F)(F)F

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR6 P46095 1/20 0.41
FPR1 P21462 1/20 0.40
FPR2 P25090 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067229 0.95 FPR1 (0.43) FPR1FPR2
Trifluoroacetic Acid SCHEMBL2068291 0.92
Trifluoroacetic Acid SCHEMBL2068383 0.90 HCRTR1 (0.41)
Trifluoroacetic Acid SCHEMBL2068372 0.89 NPC1 (0.39)
SCHEMBL2067560 0.86 FPR1 (0.44) FPR1FPR2
SCHEMBL2067533 0.86 PAK1 (0.39)
Hydrochloric Acid SCHEMBL2067441 0.85 FPR1 (0.44) FPR1FPR2
SCHEMBL2067014 0.84 HCRTR1 (0.41)
SCHEMBL2067565 0.83 NPC1 (0.43)
SCHEMBL2067304 0.81 FPR1 (0.46) FPR1FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170860-B9 BENZIMIDAZOLE DERIVATIVES PFIZER (US) 2017-02-22 EP disclosed
EP-2170860-B1 BENZIMIDAZOLE DERIVATIVES PFIZER (US) 2016-11-02 EP disclosed
US-8431597-B2 Benzimidazole derivatives PFIZER INC. (US) 2013-04-30 US disclosed
US-20120157495-A1 BENZIMIDAZOLE DERIVATIVES PFIZER INC. 2012-06-21 US disclosed
US-8148401-B2 Benzimidazole derivatives PFIZER INC. (US) 2012-04-03 US disclosed
US-20090005416-A1 BENZIMIDAZOLE DERIVATIVES PFIZER INC. 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005416-A1 BENZIMIDAZOLE DERIVATIVES BOD1L1, H1-3, BRIX1 GPR6 4265/4885FPR1 3403/4885FPR2 4184/4885
US-20120157495-A1 BENZIMIDAZOLE DERIVATIVES BOD1L1, H1-3, BRIX1 GPR6 4265/4885FPR1 3403/4885FPR2 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.